Renal and Cardiovascular Effects of Terlipressin in Patients With Cirrhosis and Ascites

This study has been completed.
Information provided by:
Hvidovre University Hospital Identifier:
First received: June 26, 2005
Last updated: March 8, 2006
Last verified: June 2005

The purpose of this study is to investigate the effect of terlipressin on myocardial perfusion and renal function.

Hypothesis: Significant improvement of renal function reflected by: glomerular filtration rate (GFR), renal blood flow (RBF), excretion of salt and metabolites in the urine and related hormones and peptides in the blood. No effect on the systolic function of the heart.

Condition Intervention Phase
Drug: Terlipressin
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double-Blind

Resource links provided by NLM:

Further study details as provided by Hvidovre University Hospital:

Study Start Date: December 2004
Estimated Study Completion Date: January 2006

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both

Inclusion Criteria:

  • Cirrhosis and ascites
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00115947

Hvidovre Hospital
Copenhagen, Hvidovre, Denmark, 2650
Sponsors and Collaborators
Hvidovre University Hospital
Principal Investigator: Aleksander Krag Krag, MD Hvidovre University Hospital
  More Information

No publications provided Identifier: NCT00115947     History of Changes
Other Study ID Numbers: 2004-000568-29
Study First Received: June 26, 2005
Last Updated: March 8, 2006
Health Authority: Denmark: Danish Medicines Agency

Additional relevant MeSH terms:
Liver Cirrhosis
Digestive System Diseases
Liver Diseases
Pathologic Processes
Antihypertensive Agents
Cardiovascular Agents
Pharmacologic Actions
Therapeutic Uses
Vasoconstrictor Agents processed this record on November 27, 2015